Practice of refined management of anti-tumor drugs based on value healthcare
10.3760/cma.j.cn111325-20220712-00629
- VernacularTitle:基于价值医疗的抗肿瘤药物精细化管理实践
- Author:
Hui QIU
1
;
Yeping JIN
;
Min YANG
;
Zongling XIA
;
Rong CHEN
;
Liying WANG
;
Haixiang XUE
;
Li LI
;
Dong SHAO
Author Information
1. 常州市第一人民医院医务处，常州 213003
- Keywords:
Refined management;
Diagnosis-related groups;
Value-based healthcare;
Anti-tumor drugs;
Muti-disciplinary therapy
- From:
Chinese Journal of Hospital Administration
2023;39(1):46-50
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the rapid increase in cancer treatment costs in China had brought a huge economic burden to society, and it was urgent to standardize the rational application of anti-tumor drugs. In the context of the reform of group payment related to disease diagnosis, a tertiary first-class hospital focused on the needs of patients and guided by value-based healthcare, established a professional and normalized refined anti-tumor drug management system, setted up a multidisciplinary diagnosis and treatment team, and promoted " Internet plus pharmaceutical services" in December 2018.From 2019 to 2021, the proportion of hospital drugs were 30.8%, 30.1%, and 27.3%, respectively. The amount of money spent on anti-tumor drugs were 83.25 million yuan, 76.41 million yuan, and 62.48 million yuan, respectively, showing a decreasing trend year by year. The practice of refined management of anti-tumor drugs fully reflected the core concept of value based healthcare, achieving closed-loop management of the entire process of drugs, improving the level of rational drug use, reducing the economic burden on patients, and providing reference for improving the level of rational use of anti-tumor drugs in public hospitals.
